Actively Recruiting
An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy
Led by Shanghai Zhimeng Biopharma, Inc. · Updated on 2025-11-20
144
Participants Needed
1
Research Sites
198 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.
CONDITIONS
Official Title
An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provide written informed consent before joining the study
- Successfully completed the prior CB03-154-EP201 study without early termination
- Met all eligibility requirements and had no major protocol deviations or adverse events that prevent entry
- Judged efficacious based on blinded data review by investigator
- Able to understand verbal and written instructions and follow study schedules
- Able to keep accurate seizure diaries
You will not qualify if you...
- Met withdrawal criteria in the prior CB03-154-EP201 study
- Have any medical condition, personal circumstance, or ongoing adverse event that poses unacceptable risk or prevents protocol adherence
- Planning to enter another clinical study or use an experimental device for epilepsy treatment during this study and for 28 days after completion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Alfred Health
Melbourne, Victoria, Australia, 3004
Actively Recruiting
Research Team
T
Terence O'Brien, professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here